Recent advances in therapies for primary myelofibrosis
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling. PMF as well as secondary MF (post-ET and post-PV MF) are the most aggressive...
Main Authors: | Vainchenker, W, Yahmi, N, Havelange, V, Marty, C, Plo, I, Constantinescu, SN |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Faculty Opinions
2023
|
Similar Items
-
Recent advances in understanding myelofibrosis and essential thrombocythemia [version 1; referees: 2 approved]
by: William Vainchenker, et al.
Published: (2016-04-01) -
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
by: Lecomte, S, et al.
Published: (2023) -
ADVANCED THERAPY IN PATIENTS WITH PRIMARY AND POSTPOLYCYTHEMIC MYELOFIBROSIS
by: A. N. Alekseeva, et al.
Published: (2017-07-01) -
Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?
by: Havelange, V, et al.
Published: (2023) -
Recent developments in myelofibrosis
by: Mesa RA, et al.
Published: (2012-07-01)